Compare Incyte Corporation (INCY) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs TORM plc — how do they compare? Incyte Corporation trades at $112.36 (market cap $22.85B), while TORM plc trades at $40.53 (market cap $4.12B). The key difference: Incyte Corporation is far larger — about 5.5× TORM plc's market cap, and TORM plc pays a 11.03% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and TORM plc for 23 Days on average.
| INCY | TRMD | |
|---|---|---|
Market Cap | $22.85B | $4.12B |
Volume | 1,927,029 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $129.93 | $41.05 |
52-Week Low | $83.80 | $19.39 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $18.35B | $4.83B |
Dividend Yield | — | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
TRMD trades at $40.54, up 4.16% today, with a bullish technical signal from moving averages and strong profitability metrics including a 35.52% net income margin and 26.84% ROE. Recent earnings showed a Q2 2026 miss but a Q4 2025 beat, while 2026 revenue is projected to grow to $1.8B. A $2.40 dividend is scheduled for September 2026, and analyst consensus is unanimously bullish with 3 buy ratings.
The outlook is positive given robust fundamentals and analyst support, but risks include spot rate volatility in the tanker market and recent insider selling. Upside potential hinges on sustained freight rates, while a downturn could pressure earnings. The stock presents a value opportunity with a low P/E of 6.59, though cyclical industry exposure warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
